Survodutide: What It Is, Phase 3 Trials and Approval Status

Veronica Hackethal | MD, MSc

Medically reviewed by Veronica Hackethal | MD, MSc, Harvard University | University of Oxford | Columbia Vagelos College of Physicians and Surgeons on August 31st, 2026.

Published on March 9th, 2026. Updated on September 28th, 2026.

Key Takeaways

  • Survodutide is investigational: it is not FDA-approved, and only people in clinical trials receive it. Doctronic can't prescribe it.

  • It's a dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim, under study for obesity and the liver disease MASH.

  • In trials it's a once-weekly injection with slow dose increases. There is no approved dose.

  • Reported side effects are mostly stomach-related, like nausea, vomiting and diarrhea, especially during dose increases.

  • FDA-approved options you can get now include Zepbound, Wegovy (weekly injection, daily pill or Wegovy HD) and Foundayo.

What Is Survodutide? Status and How It Works

Survodutide is an investigational medicine. It is not FDA-approved for any use, and only people taking part in clinical trials receive it. Doctronic can't prescribe it, and products sold online as survodutide or as research peptides are not approved.

It's a dual GLP-1 and glucagon receptor agonist, given in trials as a once-weekly injection under the skin. GLP-1 activity helps reduce hunger and improve blood sugar control. Glucagon activity is thought to raise how much energy the body uses and to act on fat in the liver, which is why it's also being studied for MASH (metabolic dysfunction-associated steatohepatitis).

Boehringer Ingelheim is testing it in Phase 3 trials (the SYNCHRONIZE program) in adults with obesity or overweight, with and without type 2 diabetes. For how it compares with an approved medicine, see survodutide vs tirzepatide.

Survodutide vs Approved and Pipeline GLP-1s

How survodutide compares with FDA-approved weight-loss medicines like Zepbound and with another medicine still in trials. To compare all GLP-1s, see the GLP-1 medications comparison chart.

Medicine

FDA status

How it's taken

Main trial result

Survodutide

Investigational, not FDA-approved

Weekly injection, trials only

Phase 3 trials in obesity and MASH

Zepbound (tirzepatide)

Approved for weight and sleep apnea

Weekly injection

20.9% at 15 mg vs 3.1% placebo, 72 weeks (SURMOUNT-1)

Wegovy (semaglutide)

Approved for weight, heart risk and MASH

Weekly injection, up to 2.4 mg

14.9% vs 2.4% placebo, 68 weeks (STEP 1)

Wegovy pill

Approved for weight, Dec 22, 2025

Daily pill, 25 mg

13.6% vs 2.4% placebo, 64 weeks (label, OASIS 4)

Wegovy HD

Approved for weight, Mar 19, 2026

Weekly injection, 7.2 mg

18.8% vs 3.9% placebo, 72 weeks (label, STEP UP)

Foundayo (orforglipron)

Approved Apr 1, 2026 for weight

Daily pill, any time

11.1% vs 2.1% placebo, 72 weeks (label)

Retatrutide

Investigational, not FDA-approved

Weekly injection, trials only

19.5% (9 mg) or 20.9% (12 mg) vs 9.4% on Ozempic 2 mg, 80 weeks (TRANSCEND-T2D-2)

Retatrutide's TRANSCEND-T2D-2 results are topline, sponsor-reported and not yet peer reviewed. The trial was open-label, in adults with type 2 diabetes, and used the efficacy estimand; A1C fell 2.2 points vs 1.8 on Ozempic 2 mg. Trials differ, so the figures can't be compared directly. More on retatrutide and retatrutide vs Ozempic.

Side Effects

In trials, side effects are common when starting survodutide or raising the dose, and most are stomach-related. Many ease as the body adjusts over the first few weeks.

Common Side Effects

  • Nausea: Feeling sick to your stomach is one of the most frequently reported side effects, especially when doses are increased, but typically improves within days to weeks

  • Vomiting: Some people experience actual vomiting, which usually occurs early in treatment and decreases as your body adapts

  • Diarrhea: Loose stools or increased bowel movements are common and may persist longer than nausea in some individuals

  • Constipation: Opposite to diarrhea, some people experience difficulty with bowel movements, which can be managed with diet and hydration changes

  • Fatigue: Feeling more tired than usual may occur, particularly during dose increases

  • Loss of appetite: The medication is designed to reduce hunger, but some people find the appetite suppression more intense than expected

Serious Side Effects

  • Pancreatitis: Inflammation of the pancreas is a rare but serious condition that causes severe belly pain that may spread to the back, often with vomiting; call 911 or get emergency care if you have these symptoms

  • Gallbladder problems: Rapid weight loss can increase the risk of gallstones, which may cause pain in the upper right abdomen

  • Severe dehydration: Vomiting and diarrhea can lead to dangerous fluid loss, causing dizziness, weakness, and confusion

  • Low blood sugar: When combined with other diabetes medications, survodutide may cause dangerously low blood sugar levels with symptoms like shakiness, sweating, and confusion

  • Thyroid tumors: Animal studies suggested a possible link to thyroid tumors, though the significance in humans is still being studied

When to Seek Medical Attention

If you're in a trial, contact your study team right away if you have severe abdominal pain, persistent vomiting, signs of dehydration, or symptoms of low blood sugar that don't improve with treatment. Also tell them if you notice yellowing of the skin or eyes, unusual bruising, or severe fatigue that interferes with daily activities.

Call 911 or get emergency care for chest pain, trouble breathing, fainting, or severe belly pain that spreads to your back. For other concerns, don't wait for a scheduled visit: your study team can help you manage side effects.

Doses Studied in Phase 3 Trials

These are the doses and schedule used in the SYNCHRONIZE Phase 3 trials, not a prescribing guide.

Trial detail

SYNCHRONIZE Phase 3 trials

Who takes part

Adults with obesity or overweight, with and without type 2 diabetes

How it's given

Once-weekly injection under the skin

Dose increases

Slower, flexible step-ups meant to reduce stomach side effects

Trial length

76 weeks

Approved dose

None: survodutide is not FDA-approved

Important: There's no approved dosing, storage or missed-dose guidance for survodutide, because it isn't approved. Trial participants follow their study team's instructions.

Possible Interactions (Based on the GLP-1 Class)

Survodutide has no approved label, so there's no official interaction list. These are possible interactions based on how GLP-1 medicines work. If you're in a trial, tell your study team about every medicine, supplement and herbal product you take.

Other GLP-1 Receptor Agonists

Using survodutide with other GLP-1 medications like semaglutide or liraglutide can increase the risk of low blood sugar and digestive side effects. These medications should not be combined without explicit medical guidance.

Insulin and Sulfonylureas

These diabetes medications significantly lower blood sugar, and combining them with survodutide may increase the risk of dangerous hypoglycemia, as with other GLP-1 medicines. The study team may need to reduce doses of these medications when starting survodutide.

Oral Birth Control

Survodutide may reduce the effectiveness of oral contraceptive pills by slowing stomach emptying and affecting how the body absorbs the medication. Using backup contraception is recommended during treatment.

Certain Blood Pressure Medications

ACE inhibitors and some other blood pressure drugs may have increased effects when combined with survodutide, potentially causing low blood pressure. Regular monitoring and possible dose adjustments may be necessary.

Thyroid Medications

Survodutide may affect how quickly your body absorbs thyroid medication like levothyroxine. Your thyroid hormone levels may need to be monitored more closely, and medication timing should be discussed with the study team.

Medications that Slow Digestion

Drugs like anticholinergics used for certain conditions can compound digestive side effects when combined with survodutide. The study team should review any medications that affect stomach function.

Potential Benefits and Unknowns

Potential benefits

  • Under study for weight loss in adults with obesity or overweight, with and without type 2 diabetes

  • Also being studied for MASH, a liver disease

  • Once-weekly injection in trials

  • Slower dose increases in trials are meant to reduce stomach side effects

  • A dual GLP-1 and glucagon action that may offer advantages over single-action medicines; trials are testing this

Unknowns

  • Not FDA-approved and only given in clinical trials; no approval date has been announced

  • How well people tolerate it outside trials, where stomach side effects were common during dose increases

  • Long-term safety is still being studied, and there's no approved label or boxed warning yet

  • May not be suitable for people with certain medical histories, including thyroid cancer concerns

Frequently Asked Questions

Get answers to common questions about survodutide.

No. Survodutide is investigational: the FDA hasn't approved it for any use, and only people in clinical trials receive it. Doctronic can't prescribe it.

No date has been announced. Outside a trial, no one can get it unless the FDA approves it. Boehringer Ingelheim's announcements are the place to watch for news on filing and approval.

Zepbound, Wegovy and Foundayo are FDA-approved for weight management now. A licensed doctor can evaluate you online for these: get evaluated for an FDA-approved GLP-1.

There's no expected timeline outside a trial, because survodutide isn't approved. In the Phase 3 trials, people take it for 76 weeks, with slow dose increases at the start.

Yes. Taking part in a clinical trial is voluntary, and you can leave at any time. Tell your study team first so they can check on you and explain what happens next.

There's no approved missed-dose guidance for survodutide. Trial participants should follow their study team's instructions.

It isn't known yet for survodutide. With approved GLP-1 medicines, some weight often comes back after stopping, especially without lasting changes to diet and activity.

Still have questions? In a trial? Ask your study team. Looking for treatment now? A licensed doctor on Doctronic can talk through FDA-approved options.

The Bottom Line

Survodutide is an investigational dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and the liver disease MASH. It isn't FDA-approved, has no approved dose, and only trial participants receive it, so Doctronic can't prescribe it. If you want treatment now, a licensed doctor can evaluate you online for FDA-approved GLP-1 options like Zepbound, Wegovy and Foundayo.

Get Weight Loss Treatment Online

Survodutide isn't available outside trials. A licensed doctor can evaluate you online for FDA-approved GLP-1 options.

Learn more

Get Support With Doctronic Now

I want to chat

Questions about survodutide?

Chat Now